Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Dietrich, S. [1 ]
Hutchings, M. [2 ,3 ]
Avigdor, A. [4 ,5 ]
Sureda, A. [6 ]
Terol, M. J. [7 ]
Bosch, F. [8 ]
Corradini, P. [9 ,10 ]
Larsen, Stauffer T. [11 ]
Dominguez, Rueda A. [12 ]
Skarbnik, A. [13 ]
Jorgensen, J. [14 ]
Goldschmidt, N. [15 ]
Gurion, R. [16 ,17 ]
Zinzani, P. L. [18 ,19 ]
Pinto, A. [20 ]
Cordoba, R. [21 ]
Bottos, A. [22 ]
Huang, Z. [23 ]
Simko, S. [24 ]
Relf, J. [25 ]
de L'Etang, Filezac A. [22 ]
Sellam, G. [22 ]
Gritti, G. [26 ,27 ]
机构：
[1] Heidelberg Univ Hosp, Clin Hematol, Oncol, Rheumatol, Heidelberg, Germany
[2] Rigshosp, Dept Hematol, Copenhagen, Denmark
[3] Rigshosp, Phase Unit 1, Copenhagen, Denmark
[4] Sheba Med Ctr, Inst Hematol, Ramat Gan, Israel
[5] Tel Aviv Univ, Tel Aviv, Israel
[6] Univ Barcelona, Dept Clin Hematol, Barcelona, Spain
[7] Univ Valencia, Hosp Clin Univ INCLIVA, Dept Hematol, Valencia, Spain
[8] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain
[9] Univ Milan, Milan, Italy
[10] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy
[11] Odense Univ Hosp, Dept Hematol, Odense, Denmark
[12] Reg & Virgen de la Victoria Univ Hosp, Med Oncol Interctr Unit, Malaga, Spain
[13] Novant Hlth Canc Inst, Lymphoma & CLL Program, Charlotte, NC USA
[14] Aarhus Univ Hosp, Dept Clin Med, Dept Haematol, Aarhus, Denmark
[15] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel
[16] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel
[17] Tel Aviv Univ, Tel Aviv, Israel
[18] Univ Bologna, IRCCS Azienda Univ Hosp, Bologna Inst Hematol, Bologna, Italy
[19] Univ Bologna, Dept Specialist Diagnost & Expt Med, Bologna, Italy
[20] Natl Canc Inst Fdn G Pascale IRCCS, Dept Hematol, Neapel, Italy
[21] Fdn Jimenez Diaz Univ Hosp, Dept Hematol, Madrid, Spain
[22] F Hoffmann La Roche Ltd, Basel, Switzerland
[23] F Hoffmann La Roche Ltd, Shanghai, Peoples R China
[24] Genentech Inc, San Francisco, CA USA
[25] F Hoffmann La Roche Ltd, Welwyn Garden City, England
[26] Azienda Osped Papa Giovanni XXIII, Hematol Unit, Bergamo, Italy
[27] Azienda Osped Papa Giovanni XXIII, Bone Marrow Transplant Unit, Bergamo, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P404
引用
收藏
页码：209 / 209
页数：1
相关论文
共 50 条
  • [21] Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Shah, Nirav N.
    Flinn, Ian
    Kwon, Mi
    Jaeger, Ulrich
    Briones, Javier
    Bachy, Emmanuel
    Blaise, Didier
    Boissel, Nicolas
    Kato, Koji
    Riedell, Peter A.
    Frigault, Matthew J.
    Shune, Leyla O.
    Teshima, Takanori
    Ciceri, Fabio
    Fleming, Shaun A.
    Ferrari, Silvia
    Pearson, David
    Whalen, Jeanne
    Zia, Aiesha
    Davis, Jaclyn
    Masood, Aisha
    Dickinson, Michael
    Barba, Pere
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S532 - S533
  • [22] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Foss, Francine
    Huntington, Scott
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
  • [23] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    McMillan, A.
    Sehn, L.
    Herrera, A.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 80
  • [24] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [25] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [26] Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Li, Yanyan
    Zhang, Mengqi
    Lu, Feinan
    Song, Yuqin
    Zhu, Jun
    BLOOD, 2023, 142
  • [27] Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥ 2 Prior Therapies
    Song, Yu-Qin
    Zhang, Hui-Lai
    Huang, Hui-Qiang
    Zhang, Qing-Yuan
    Jing, Hong-Mei
    Wang, Chao
    Wu, Chun
    Li, Dong-Hang
    Dai, Yu
    Humphrey, Kathryn
    Zhu, Jun
    BLOOD, 2022, 140 : 12050 - 12051
  • [28] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
    Dickinson, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Trneny, Marek
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Balari, Anna Sureda
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    BLOOD, 2017, 130
  • [30] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
12345